Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today, October 25, 2021, first trading day at Nasdaq First North Growth Market and new website.
Commencing today, Initiator Pharma shares are traded at the Nasdaq First North Growth Market under the ticker INIT with ISIN DK0060775872. Shareholders in Initiator Pharma will not have to take any action with regards to the change of listing venue. In connection with the list change the company has announced an updated website, www.initiatorpharma.com.
“I appreciate how Nasdaq First North has welcomed Initiator Pharma in our journey towards making a difference for patients who suffers from erectile dysfunction or neuropathic pain. We see the list change as a natural progression for our ambition to create a global awareness of our programs and the significant unmet needs they address. The new market place makes the Initiator Pharma share accessible for the many international investors who use the Nasdaq platforms,” says Claus Elsborg Olesen, CEO of Initiator Pharma. “We are looking forward to reach and deliver on several significant milestones over the next 18 months. These deliverables will be transformational for Initiator Pharma, benefitting the company and its shareholders. We are welcoming you all to take part in our exciting journey.”
Redeye AB has been appointed as the company’s Certified Adviser on Nasdaq First North. In connection with the list change, DLA Piper Denmark and DLA Piper Sweden have acted as the company’s legal advisor.